VANCOUVER, BC , Aug. 22, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF ) ("BioVaxys" or the "Company") highlights the potential of its novel lipid-in-oil delivery platform, DPXTM, across multiple infectious disease studies and announces its plans for partnering and further development.
BioVaxys' DPXTM technology ("DPX") is a patented delivery platform that can incorporate a range of bioactive molecules to produce targeted, long-lasting immune responses enabled by various formulated components. The DPX platform facilitates antigen delivery to regional lymph nodes and has been demonstrated to induce robust and durable T cell and B cell responses in pre-clinical and clinical studies for both cancer and infectious disease. Key findings demonstrated in completed infectious disease studies, which are discussed in more detail below include: In a phase 1 human study for respiratory syncytial virus (RSV), DPX-RSV demonstrated antigen-specific immune responses in 93% of subjects, with 100% of responders in the 25μg dose cohort maintaining antigen-specific immunity one year post vaccination.
Animal challenge studies with DPX-Based Anthrax vaccine demonstrated 100% immunity following a single injection compared to current vaccines which require more than one dose. In a pre-clinical murine model, DPX-rHA for influenza achieves higher antibody levels than standard Alum rHA Vaccine and protects against multiple flu strains. BioVaxys President and Chief.